GoodRx Holdings, Inc. (NASDAQ:GDRX) shares are trading higher after the company reported fourth-quarter FY23 results and issued first-quarter revenue guidance above estimates.
Revenue and adjusted revenue increased 7% Y/Y to $196.6 million, beating the consensus of $195.8 million.
Prescription transactions revenue increased 11% to $143.9 million, mainly driven by an 8% increase in Monthly Active Consumers and quarter-specific favorability related to certain client contracts.
GoodRx exited the quarter with over 7 million consumers of prescription-related offerings. Monthly Active Consumers were 6.4 million compared to 5.9 million …